Drug therapies in bronchopulmonary dysplasia: debunking the myths
Introduction
The term ‘bronchopulmonary dysplasia’ (BPD) was first described in 1967 by Northway et al.,1 and despite the ongoing researches to improve the neonatal respiratory care, BPD continues to impose a considerable risk for mortality and long-term morbidity. Several devices and strategies have been developed to provide optimum respiratory support to the newborn infants, and several drug therapies have also been used in an attempt to prevent BPD or to mitigate the course of the ‘established’ condition. Although there is considerable evidence to support the ‘routine’ use of some therapies, most therapies remain individual- or institution-specific, based on anecdotes, evidence of short-term (but not clinically meaningful) benefits, beliefs, and myths. There is also a considerable variation in clinical practices to define and establish the diagnosis of BPD,2 upon which the infants receive therapies. In this context, we have tried to provide the available evidence for drug therapies and hope that the clinicians will find this useful in appraising their own current practices.
Section snippets
Prevention of BPD
As with all the clinical conditions, the ‘ideal’ management strategy would be to prevent BPD; once established, the treatment for BPD remains mostly supportive.
Defining BPD
Since Bancalari et al. proposed a definition of BPD 30 years ago, based on clinical characteristics (the need for oxygen on 28 of the first 28 days with chest radiographic changes), different definitions of BPD have evolved.80 The National Institutes of Health Consensus in 2001 helps the clinician to define BPD with more information about its severity.81 However, the definition of BPD and the decision to initiate therapies is largely based on whether the infant needs oxygen therapy, and
Conclusion
Since the first description of BPD by Northway et al. in 1967, there have been great improvements in our knowledge and understanding of its pathogenesis and its risk factors. In parallel, newer strategies of ventilation and drug therapies have developed. Population characteristics of infants at high risk of BPD have also changed considerably over this 40-year period. However, BPD remains a major challenge to the clinicians, and continues to impose major risks of mortality and long-term
Conflict of interest statement
None declared.
Funding sources
None.
References (92)
- et al.
Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition
Semin Neonatol
(2003) - et al.
Efficacy of caffeine in treatment of apnea in the low-birth-weight infant
J Pediatr
(1977) Methylxanthine therapy in premature infants: sound practice, disaster or fruitless by way?
J Pediatr
(1999)- et al.
Sequelae of caffeine treatment in preterm infants with apnea
J Pediatr
(1979) Bronchopulmonary dysplasia – oxidative stress an anti-oxidants
Semin Neonatol
(2003)- et al.
Giving small babies oxygen: 50 years of uncertainty
Semin Neonatol
(2002) - et al.
Inhaled nitric oxide in premature neonates with severe hypoxemic respiratory failure: a randomised controlled trial
Lancet
(1999) - et al.
Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease
J Pediatr
(1993) - et al.
Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease
J Pediatr
(1987) - et al.
Bronchopulmonary dysplasia: clinical presentation
J Pediatr
(1979)
Pulmonary disease following respiratory therapy of hyaline membrane disease: bronchopulmonary dysplasia
N Engl J Med
Prophylactic corticosteroids for preterm birth
Cochrane Database Syst Rev
Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease
Cochrane Database Syst Rev
Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants
Cochrane Database Syst Rev
Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants
Cochrane Database Syst Rev
Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants
Cochrane Database Syst Rev
Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome
Cochrane Database Syst Rev
Synthetic surfactant for respiratory distress syndrome in preterm infants
Cochrane Database Syst Rev
Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome
Cochrane Database Syst Rev
A multicentre, randomised controlled trial of lucinactant versus poractant alpha among very premature infants at high risk of respiratory distress syndrome
Pediatrics
A multicentre, randomised, masked, comparison trial of lucinactant, colfosceril palmitate and beractant for the prevention of respiratory distress syndrome
Pediatrics
Methylxanthine treatment for apnoea in preterm infants
Cochrane Database Syst Rev
Long term outcome of premature infants treated with theophylline
Semin Perinatol
Early childhood developmental follow up of infants with GMH/IVH: effect of methylxanthine therapy
Am J Perinatol
Cerebral palsy in very low birth weight infants surviving to 2 years with modern neonatal intensive care
Am J Perinatol
Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants
Pediatrics
New drug application: CAFCIT (NDA) 02073
Caffeine therapy for apnea of prematurity
N Engl J Med
Long term effects of caffeine therapy for apnea of prematurity
N Engl J Med
Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation
Arch Dis Child
Can changes in clinical practice decrease the incidence of severe retinopathy in very low birth weight infants?
Pediatrics
Retinopathy of prematurity and pulse oximetry: a national survey of recent practices
J Perinatol
Relation of target SpO2 levels and clinical outcome in ELBW infants on supplemental oxygen
Pediatr Res
Retinopathy of prematurity: a comparison between two centers aiming for different pulse oximetry saturation levels
Biol Neonate
A cautionary tale about supplemental oxygen: the albatross of neonatal medicine
Pediatrics
Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation
J Appl Physiol
Surfactant composition and function in a primate model of infant chronic lung disease: effect of inhaled nitric oxide
Pediatr Res
Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease
Am J Physiol Lung Cell Mol Physiol
Nitric oxide for respiratory failure in infants born at or near term
Cochrane Database Syst Rev
Inhaled nitric oxide for respiratory failure in preterm infants
Cochrane Database Syst Rev
Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. The Franco-Belgium Collaborative NO Trial Group
Lancet
Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants
Arch Dis Child
Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO Multicentre Randomised Controlled Trial
Pediatrics
Inhaled nitric oxide for premature infants with severe respiratory failure
N Engl J Med
Cited by (23)
Bronchopulmonary dysplasia: Myths of pharmacologic management
2017, Seminars in Fetal and Neonatal MedicineCitation Excerpt :The answer appears to be “no.” Two comprehensive reviews of diuretic therapy indicate some short-term improvement in pulmonary function, but without any substantial reduction in ventilator support or duration of treatment. No long-term benefits, such as a reduction in mortality, duration of positive pressure ventilation or oxygen use, or length of hospital stay have been shown [8,9]. Administration of diuretics to an infant with BPD will generally result in a diuresis, with subsequent loss of salt and water.
Noninvasive Support: Does It Really Decrease Bronchopulmonary Dysplasia?
2016, Clinics in PerinatologyCitation Excerpt :Unfortunately, neither antenatal corticosteroids nor surfactant have significantly decreased the incidence of BPD.28–30 Additionally, only 3 pharmacologic interventions—caffeine, vitamin A, and dexamethasone—have been shown to prevent the development of BPD in at-risk infants.33,34 Postnatal dexamethasone, used early and without consideration of the baseline risk of developing BPD, has been demonstrated to increase the risk of cerebral palsy, and its use was discouraged by the American Academy of Pediatrics in 2002.35–37
Lithium protects against glucocorticoid induced neural progenitor cell apoptosis in the developing cerebellum
2014, Brain ResearchCitation Excerpt :However, in 2010, a revised policy recommended that the clinician balance potential adverse and beneficial effects when deciding whether to administer postnatal GC therapy (Watterberg, 2010). Currently, this treatment remains highly individual/institutional specific (Tin and Wiswell, 2009), suggesting that there is no clear consensus for its use. Despite these concerns, surprisingly little is known about how GC stimulation disrupts cerebellar development.
Human amnion epithelial cells reduce ventilation-induced preterm lung injury in fetal sheep
2012, American Journal of Obstetrics and GynecologyCitation Excerpt :In short, maintaining the normal lung architecture required for ongoing alveolar development and thereby, hopefully, preventing BPD. We believe that these findings represent a significant advancement over the current management of BPD, which is largely supportive.16 The majority of previous studies using hAECs in lung injury have addressed their potential use in small animal models of adult lung disease, using injurious insults such as bleomycin or naphthalene.5-7
The premature infant with chronic lung disease/bronchopulmonary dysplasia: Follow-up
2011, Anales de Pediatria Continuada